This article was originally published in Start Up
Executive SummaryBy all accounts, 1997 was a bad year for small medical device companies trying to go public. Does the recent IPO of hearing-aid company Symphonix Devices presage a good market in 1998 for other medical device companies with early-stage technologies?
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.